Several clinical and biological factors are utilized for both clinical-prognostic stratification and therapeutic targeting in metastatic CRC, including initial tumor burden, CEA levels, performance status, BRAF and RAS mutations, and microsatellite status [8]. Here, BRAF is linked to neoplasm.